Description: The North America Mass Spectrometry Market is poised to surge from US$ 2.6 Billion in 2024 to US$ 4.87 Billion by 2033, driven by a 7.21% CAGR. Key growth areas include pharmaceutical, environmental analysis, and food safety sectors, powered by advancements in mass spectrometry technology enhancing sensitivity and precision. Major drivers include increased demand in the pharmaceutical and biotechnology sectors, advancements in hybrid and high-resolution technologies, and growing applications in

Description: The North American Nucleic Acid Amplification Testing (NAAT) market will reach $7.64 billion by 2033, growing from $3.28 billion in 2024 with a CAGR of 9.87%. Driven by technological advances, rising diagnostic demand, and widespread applications, NAAT proves critical in identifying infectious diseases and genetic mutations. Notably, innovation, automation, and government support bolster the market's expansion. Despite regulatory hurdles and high costs, ongoing collaborations aim to enhance affo

Description: With us today are Rainer Blair, our President and Chief Executive Officer; and Matt McGrew, our Executive Vice President and Chief Financial Officer. And with that, I'd like to turn the call over to Rainer.

Description: Danaher (DHR) stock has seen modest movement over the past month, gaining 3%. In contrast, the past three months marked a steadier 11% climb. Investors are weighing recent performance against the company’s longer-term trends. See our latest analysis for Danaher. Danaher's share price momentum has held up over the past quarter with a steady 11% gain, even as its 1-year total shareholder return remains slightly negative at -3.76%. This mix of recent strength and stagnant longer-term performance...

Description: Deutsche Bank analyst David Begleiter reiterated his Buy rating on the shares. His price target is $46

Description: Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Description: The United States STD Diagnostics Market is set to grow from US$ 5.06 billion in 2024 to US$ 8.49 billion by 2033, achieving a CAGR of 5.91% from 2025 to 2033. Key growth drivers include rising STD prevalence, technological advancements, increased awareness, and supportive government initiatives. Rapid point-of-care tests and molecular diagnostics are gaining traction, while high costs and regulatory hurdles persist as challenges. Major markets like California, Texas, New York, and Florida lead

Description: Deutsche Bank analyst David Begleiter reiterated his Buy rating on the shares. His price target is $46

Description: Key Insights The projected fair value for Danaher is US$218 based on 2 Stage Free Cash Flow to Equity With US$227 share...

Description: Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: The HPV testing and Pap test market is set to grow from USD 2.44 billion in 2025 to USD 3.94 billion by 2030, with a CAGR of 10.0%. This growth is fueled by increased awareness of cervical cancer and government-led screening initiatives. Consumables lead the market, driven by demand for reagents and collection kits essential for testing. While cervical cancer screening dominates, vaginal cancer screening is poised for rapid growth, aided by enhanced diagnostic capabilities. The Asia Pacific regi

Description: BillionToOne, Inc. (NASDAQ:BLLN) is one of the stocks Jim Cramer expressed his thoughts on. Cramer noted that he is a “big fan” of the industry the company is a part of, as he stated: “Where do I come down on this thing? Honestly, I really like it. BillionToOne is playing in an industry that I’m […]

Description: Many investors define successful investing as beating the market average over the long term. But if you try your hand...

Description: SOLV vs. DHR: Which Stock Is the Better Value Option?

Description: Following the success of i3 2025, IDBS, a Danaher company and leading provider of cloud software for BioPharma companies, is excited to announce that its flagship customer and partner event, i3 2026, will take place in Boston, USA on May 18, 2026.

Description: If you have decades of investing runway left, consider these two top healthcare stocks.

Description: Danaher (DHR) shares have edged modestly higher over the past month, gaining about 7%. Investors seem to be weighing up recent performance and the company’s underlying growth trends as they look for clues about its outlook. See our latest analysis for Danaher. While Danaher has been clawing back some ground with a 6.6% share price gain over the last month, the bigger picture tells a more cautious story, with a one-year total shareholder return of -9.4%. Recent momentum suggests investors are...

Description: Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Jefferies Global Healthcare Conference in London, UK on Tuesday, November 18, 2025 at 11:00 a.m. GMT. The event will be simultaneously webcast on www.danaher.com.

Description: SOLV vs. DHR: Which Stock Is the Better Value Option?

Description: The Biopsy Devices market is projected to reach $4.02 billion by 2033, growing from $2.43 billion in 2024 at a CAGR of 5.75%. This growth is driven by personalized care demand, rising cancer cases, and minimally invasive treatments enhancing patient comfort. Key biopsy devices include needle, punch, and surgical tools for various medical needs. Advancements in biopsy technology ensure precise, early cancer detection and improved patient outcomes. Leading companies like Cardinal Health, Hologic,

Description: Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Description: Urban areas in states like New South Wales and Victoria lead the market, bolstered by strong infrastructure and investment in cutting-edge dental technologies. Recent developments see major companies like Danaher and Dentsply Sirona expanding their product offerings to cater to evolving market needs. Australian Dental Diagnostics and Surgical Equipment Market Australian Dental Diagnostics and Surgical Equipment Market Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Australia Dental Diagnostics an

Description: In the last year, many Danaher Corporation ( NYSE:DHR ) insiders sold a substantial stake in the company which may have...

Description: Titan Holdings has launched a new operating company, Tala Health, Fortune has exclusively learned.

Description: The HbA1c testing market presents opportunities driven by rising Type 2 diabetes cases and advancements in testing technologies. Supportive healthcare initiatives and increased awareness enhance demand. Strategic insights, competitive analysis, and diverse applications across settings highlight key investment areas. HbA1c Testing Market HbA1c Testing Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "HbA1c Testing Market Size, Share, Growth, Trends and Forecast 2025-2033" report has been adde

Description: Danaher's (NYSE:DHR) stock is up by 9.3% over the past three months. Given that the stock prices usually follow...

Description: When ultra-rich investors start coalescing into the same names or put an unusually large amount of money into a single stock, that should raise more interest. That’s exactly what we’re seeing with UnitedHealth (NYSE:UNH), Visa (NYSE:V), and Danaher (NYSE:DHR). These investors have far more resources than the average Joe. Perhaps, they know something about these ... The Richest 0.1% Are Buying These 3 Dividend Stocks Right Now

Description: Mexican Dental Implant Market Mexican Dental Implant Market Dublin, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The "Mexico Dental Implant Market Forecast & Trends 2025-2033" has been added to ResearchAndMarkets.com's offering. The Mexico Dental Implant Market is expected to reach US$ 161.02 million in 2033, from US$ 87.88 million in 2024, at a CAGR of 6.96% during the years 2025-2033. This market is expected to be pushed by growing dental tourism, rising incidence of oral diseases, growing geriatric popu

Description: Danaher Corporation's ( NYSE:DHR ) stock was strong despite it releasing a soft earnings report last week. Our analysis...

Description: Danaher’s third quarter was marked by solid execution across its core businesses, with management citing bioprocessing momentum and a stronger-than-anticipated performance in respiratory diagnostics as key drivers. CEO Rainer Blair highlighted that demand for monoclonal antibody production remained robust, propelling bioprocessing growth, while Cepheid’s respiratory testing revenues benefited from customers ordering earlier than usual. Management also pointed to disciplined cost management and o

Description: Explore Danaher's (DHR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Description: Diversified science and technology company Danaher (NYSE:DHR) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.4% year on year to $6.05 billion. On the other hand, next quarter’s revenue guidance of $6.70 billion was less impressive, coming in 4.7% below analysts’ estimates. Its non-GAAP profit of $1.89 per share was 9.8% above analysts’ consensus estimates.

Description: Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently highlighted. Discussing the post-earnings rally of the stock, Cramer remarked: “Then there’s Danaher, DHR, the life sciences and diagnostic equipment company, which has been a huge disappointment for my Charitable Trust for so long. Not today, though. Today, Danaher gave us the quarter we’ve […]

Description: The demand for Cell Culture Media Storage Containers is rising due to biopharma growth, regenerative medicine, and eco-friendly trends. Opportunities lie in advanced, sustainable storage solutions, single-use systems, and automation for improved compliance and efficiency, driven by stricter GMP standards and bioprocessing needs. Cell Culture Media Storage Containers Market Cell Culture Media Storage Containers Market Dublin, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The "Cell Culture Media Storage Conta

Description: Danaher (DHR) reported net profit margins of 14.4%, down from 16.6% a year ago, while earnings have declined at an average annual rate of 5.6% over the past five years. Despite this pullback, analysts expect Danaher's earnings to grow 16.72% annually, which is ahead of the broader US market’s projected 15.5% yearly growth. However, revenue growth forecasts lag at 5.2% per year compared to the market’s 10%. With no major or minor risks flagged in the current data, investors are weighing the...

Description: Danaher's stock has seen its Fair Value Estimate increase to $247.30 from $244.50, even as growth projections become more mixed across the industry. Recent analyst commentary shows a split between optimism about stabilization within key segments and caution about the pace of recovery ahead. Stay tuned to learn how you can keep up with the evolving Danaher story as market views continue to shift. What Wall Street Has Been Saying 🐂 Bullish Takeaways BofA continues to rate Danaher as a Buy,...

Description: We recently published 10 Stocks Leaving Wall Street in the Dust. Danaher Corp. (NYSE:DHR) is one of the best performers on Tuesday. Danaher bounced back by 5.94 percent on Tuesday to close at $220.77 apiece after achieving an improved earnings performance in the third quarter of the year. In an updated report, Danaher Corp. (NYSE:DHR) […]

Description: Companies in The News Are: KO, DHR, RTX, VST

Description: Danaher Corporation (NYSE:DHR) is one of the stocks in Jim Cramer’s recent game plan. Cramer showed slight optimism around the company’s upcoming earnings, as he remarked: “… and Charitable Trust club name Danaher, one of our biggest laggards, may report the first of many good quarters after a shocking multiple-year dry spell for this once […]

Description: ↗️ Warner Bros. Discovery (WBD): The media company said it had begun reviewing strategic alternatives after being approached about potential deals. Shares jumped nearly 11%. ↗️ RTX (RTX): The defense company raised its annual forecast on high demand for munitions and missiles.

Description: Shares of Danaher surged Tuesday after the medical research company beat third-quarter forecasts on the back of its bioprocessing division.

Description: Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index climbing 0.1% and th

Description: Danaher Corp (DHR) reports robust Q3 performance with $6.1 billion in sales, a 10% increase in adjusted EPS, and a $2 billion share repurchase initiative.

Description: The company's third-quarter earnings pleased investors.

Description: Shares of diversified science and technology company Danaher (NYSE:DHR) jumped 7.5% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst expectations for revenue and profit. Danaher announced revenue grew 4.4% from the previous year to $6.05 billion, ahead of the $6.01 billion consensus estimate. The company’s adjusted earnings per share also came in strong at $1.89, higher than the anticipated $1.72. The report was not entirely positive

Description: Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.2% and the Health Ca

Description: The life sciences and diagnostics company posted sales of $6.05 billion and stands to benefit from an increase in pharmaceutical-research investment as tariff uncertainty eases.

Description: DHR Q3 earnings and sales beat estimates, driven by solid segment growth and stronger operating margins.

Description: The Dow Jones and the S&P 500 were up, while the Nasdaq Composite was flat in late-morning trading T

Description: Danaher's (DHR) fiscal third-quarter results came in stronger than Wall Street's forecasts, while th

Description: Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: REDWOOD CITY, Calif. & EMERYVILLE, Calif., October 21, 2025--Profluent Bio's AI-driven protein design and IDT’s enzymology and genomics expertise unite to explore new paths for developing novel enzyme variants.

Description: US equity futures were pointing lower on Tuesday as investors assess the critical minerals deal betw

Description: Danaher (DHR) delivered earnings and revenue surprises of +10.53% and +0.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Investing.com -- Danaher reported third-quarter results that topped analyst expectations, while its full-year profit outlook narrowly missed consensus estimates at the midpoint.

Description: Diversified science and technology company Danaher (NYSE:DHR) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 4.4% year on year to $6.05 billion. On the other hand, next quarter’s revenue guidance of $6.70 billion was less impressive, coming in 4.7% below analysts’ estimates. Its non-GAAP profit of $1.89 per share was 9.8% above analysts’ consensus estimates.

Description: On a per-share basis, the Washington-based company said it had profit of $1.27. Earnings, adjusted for one-time gains and costs, came to $1.89 per share. The results surpassed Wall Street expectations.

Description: Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025.

Description: LH vs. DHR: Which Stock Is the Better Value Option?

Description: Diversified science and technology company Danaher (NYSE:DHR) will be announcing earnings results this Tuesday morning. Here’s what to expect.

Description: As investors enters shutdown week three, a US-China trade war, credit gesticulation, and an incoming oil glut are weighing on the market.

Description: Danaher (DHR) drew renewed attention after a well-followed analyst at Rothschild & Co. Redburn shifted the stock rating from Buy to Hold, citing concerns about premium valuation, uncertainty regarding China’s recovery, and questions in the diagnostic segment. See our latest analysis for Danaher. Danaher shares have edged higher in recent weeks, but the positive momentum comes after a tough stretch, with its 1-year total shareholder return down over 23%. High-profile ratings changes and...

Description: Whether you see them or not, industrials businesses play a crucial part in our daily activities. They are also bound to benefit from a friendlier regulatory environment with the Trump administration, and this excitement has led to a six-month gain of 38.5% for the sector - higher than the S&P 500’s 25.9% return.

Description: DHR gears up for Q3 results with steady earnings estimates and mixed segment trends across Life Sciences, Biotechnology and Diagnostics.